Book Chapter

An G and Morris ME. Chapter 3 of the book Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition to Inhibition Strategies in Chemotherapy. book edited by Alejandro Sosnik, Reina Bendayan. Springer 2019. ISBN-10: 0128164344.

An G and Morris ME, Enzyme- and Transporter-Based Drug-Drug Interactions- Progress and Future Challenge, book edited by Pang KS, Rodrigues AD and Peter RM. Springer 2010, pp.555-584.

Peer Reviewed Articles

  1. D’Cunha R, Schmidt R, Widness JA, Mock DM, Yan X, Cress GA, Kuruvilla D, Veng-Pedersen P, An G*. Target-Mediated Disposition Population Pharmacokinetics Model of Erythropoietin in Premature Neonates Following Multiple Dosing Regimens. European Journal of Pharmaceutical Sciences. 2019 July 21 [Epub ahead of print] (PubMed link) * Corresponding author

  2. D'Cunha R, Murry DJ, An G*. Nilotinib alters the efflux transporter-mediated pharmacokinetics of afatinib in mice. Journal of Pharmaceutical Sciences. 2019 Jun 1. [Epub ahead of print] (PubMed link) * Corresponding author

  3. Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Cegielski JP, Kempker RR, Heysell SK, Peloquin CA. Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Antimicrob Agents Chemother. 2019; 63(7). pii: e00279-19. (PubMed link)

  4. Bach T, Bae S, D'Cunha R, Winokur P, An G*. Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. J Pharm Biomed Anal. 2019;171:111-117. (PubMed link) * Corresponding author

  5. Alghamdi, WA, Alsultan, A, Al-Shaer, MH, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Schmidt S, Heysell SK, Kempker RR, Cegielski P, Peloquin CA. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00055-19. (PubMed link)

  6. An G*, Murry DJ, Gajurel K, Bach T, Deye G, Stebounova LV, Codd EE, Horton J, Gonzalez AE, Garcia HH, Ince D, Hodgson-Zingman D, Nomicos EYH, Conrad T, Kennedy J, Jones W, Gilman RH, Winokur P*. Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02255-18. (PubMed link) * Corresponding author

  7. D’Cunha R, Widness JA, Yan X, Schmidt R, Veng-Pedersen P, An G*. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses. Journal of Clinical Pharmacology 2019;59(6):835-846 (PubMed link) * Corresponding author

  8. An G*, Schmidt RL, Mock DM, Veng-Pedersen P, Widness JA,. Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin. The AAPS Journal. 2018 Nov 26;21(6):1-4. (PubMed link) * Corresponding author

  9. Bach T, Jiang Y, Zhang X, An G*. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study. J Clin Pharmacol. 2019;59(3):394-405. (PubMed link) * Corresponding author

  10. Yu L, Qi H, An G, Bao J, Ma B, Zhu J, Ouyang G, Zhang P, Fan H, Zhang Q. Association between metabolic profiles in urine and bone mineral density of pre- and postmenopausal Chinese women. Menopause. 2019; 26(1):94-102. (PubMed link)

  11. D'Cunha R, Bach T, Young BA, Li P, Nalbant D, Zhang J, Winokur P, An G*. Quantification of Cefepime, Meropenem, Piperacillin and Tazobactam in Human Plasma using a Sensitive and Robust LC-MS/MS Method- Part I. Assay Development and Validation. Antimicrob Agents Chemother. 2018;62(9). Pii:e00859-18. (PubMed link) . * Corresponding author

  12. D'Cunha R, Bach T, Young BA, Li P, Nalbant D, Zhang J, Winokur P, An G*. Quantification of Cefepime, Meropenem, Piperacillin and Tazobactam in Human Plasma using a Sensitive and Robust LC-MS/MS Method- Part II. Stability Evaluation. Antimicrob Agents Chemother. 2018;62(9). Pii:e00861-18. (PubMed link) . * Corresponding author

  13. Marsh E, Verhoven SM, Groszek JJ, Fissell WH, An G, Patel P, Creech B, Shotwell M. Beta-lactam carryover in arterial and central venous catheters is negligible. Clin Chim Acta 2018; 486:265-268. (PubMed link)

  14. Mock DM, Nalbant D, Kyosseva SV, Schmidt RL, An G, Matthews NI, Vlaar APJ, van Bruggen R, de Korte D, Strauss RG, Cancelas JA, Franco RS, Veng-Pedersen P, Widness JA. Development, validation, and potential applications of biotinylated red blood cells for posttransfusion kinetics and other physiological studies: evidenced-based analysis and recommendations.Transfusion.2018;58(8):2068-2081.(PubMed link).

  15. Bae S, D'Cunha R, Shao J, An G*. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. European Journal of Pharmaceutical Sciences 2018;117:27-34. (PubMed link) * Corresponding author

  16. Wang Y, Guo SH, Shang XJ, Yu LS, Zhu JW, Zhao A, Zhou YF, An G, Zhang Q, Ma B. Triptolide induces Sertoli cell apoptosis in mice via ROS/JNK-dependent activation of the mitochondrial pathway and inhibition of Nrf2-mediated antioxidant response. Acta Pharmacologica Sinica. 2018;39(2):311-327. (PubMed link)

  17. Awasthi R, An G, Donovan MD, Boles Ponto LL. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach. Journal of Pharmaceutical Sciences 2018; 107(2): 745-755. (PubMed link)

  18. An G*, Ohls RK, Christensen RD, Widness JA, Mock DM, Veng-Pedersen P. Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of Pharmaceutical Sciences. 2017;106(6):1644-1649. (PubMed link) * Corresponding author

  19. Jiang Y, Milavetz G, James MO, An G*. A Mechanism-based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Auto-Inhibition in Rats. Journal of Pharmaceutical Sciences. 2017;106(5):1396-1404. (PubMed link) * Corresponding author

  20. Tang B, Shang X, Qi H, Li J, Ma B, An G, and Zhang Q. Metabonomic analysis of fatty acids in seminal plasma between healthy and asthenozoospermic men based on gas chromatography mass spectrometry. Andrologia. 2017; 49(9): 1-13. (PubMed link)

  21. Kuruvilla D, Widness JA, Nalbant D, Schmidt RL, Mock DM, An G, and Veng-Pedersen P. Estimation of Adult and Neonatal RBC Lifespans in Anemic Neonates using RBCs Labeled at Several Discrete Biotin Densities. Pediatric Research. 2017;81(6):905-910. (PubMed link)

  22. An G*. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview. Journal of Clinical Pharmacology. 2017;57(2):137-150. (PubMed link) * Corresponding author

  23. D'Cunha R, Bae S, Murry DJ, An G*.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharmaceutics & Drug Disposition. 2016;37(7):397-408. (PubMed link) * Corresponding author

  24. An G*, Widness JA, Mock DM, Veng-Pedersen P. A Novel Physiology-Based Mathematical Model to Estimate Red Blood Cell Lifespan in Different Human Age Groups. The AAPS Journal. 2016;18(5):1182-91. (PubMed link) * Corresponding author

  25. Bei D and An G*. Pharmacokinetics and tissue distribution of 5,7-dimethoxyflavone in mice following single dose oral administration. Journal of Pharmaceutical and Biomedical Analysis. 2016;119:65-70. (PubMed link)* Corresponding author
  26. Qi H, Bao J, An G, Ouyang G, Zhang P, Wang C, Ying H, Ouyang P, Ma B, Zhang Q. Association between the metabolome and bone mineral density in pre- and post-menopausal Chinese women using GC-MS. Molecular Biosystems. 2016;12(7):2265-75. (PubMed link)

  27. Bi Y, Deng J, Murry DJ, An G*. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. AAPS J. 2015 Nov 11. * Corresponding author.(PubMed link)

  28. Ma B, Qi H, Li J, Xu H, Chi B, Zhu J, Yu L, An G, Zhang Q. Triptolide disrupts fatty acids and peroxisome proliferator-activated receptor (PPAR) levels in male mice testes followed by testicular injury: A GC-MS based metabolomics study. Toxicology. 2015;336:84-95(PubMed link)

  29. An G*, Kaur Mukker J, Derendorf H, Frye RF. Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. Journal of Clinical Pharmacology 2015 Jun 10. [Epub ahead of print].* Corresponding author.(PubMed link)

  30. Ziegler D, Duan WR, An G, Thomas JW, Nothaft W. A randomized double-blind, placebo- and active-controlled study of T-type calcium channel blocker ABT-639 in diabetic patients with peripheral neuropathic pain. Pain 2015;156(10):2013-20.(PubMed link)

  31. An G*, Liu W, Dutta S. Small molecule compounds exhibiting target-mediated drug disposition (TMDD) - a case example of ABT-384. Journal of Clinical Pharmacology 2015;55(10):1079-85.* Corresponding author.(PubMed link)

  32. Alsultan A, An G, Peloquin CA. Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients with Tuberculosis.Antimicrob Agents Chemother. 2015;59(7):3800-7.(PubMed link)

  33. Cope JM, Bushwitz J, An G, Antigua A, Patel A, Zumberg M. Reply: clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy.Ann Pharmacother 2015;49(5):614-5.(PubMed link)

  34. An G*, Liu W, Duan WR, Nothaft W, Awni W, Dutta S. Population Pharmacokinetics and Exposure-Uric Acid Analyses After Single and Multiple Doses of ABT-639, a Calcium Channel Blocker, in Healthy Volunteers. AAPS J. 2015;17(2):481-92. * Corresponding author.(PubMed link)

  35. Bei D and An G*. Quantification of 5,7-Dimethoxyflavone in Mouse Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and its Application to a Pharmacokinetic Study. Journal of Chromatography B 2015 Jan; 978-979:11-7. * Corresponding author.(PubMed link)

  36. Fleisher B, Uum J, Shao J, and An G*. Ingredients in Fruit Juice Interact with Dasatinib through Inhibition of BCRP: A New Mechanism of Beverage-Drug Interaction. Journal of Pharmaceutical Sciences 2015 Jan;104(1):266-75 * Corresponding author.(PubMed link)

  37. Cope J, Bushwitz J, An G, Antigua A, Patel A, and Zumberg M. Clinical experience with fondaparinux in critically ill patients with moderate to severe renal impairment and renal failure requiring renal replacement therapy. Annals of Pharmacotherapy 2015 ;49(3):270-7(PubMed link)

  38. Egelund EF, Isaza R, Brock AP, Alsultan A, An G, and Peloquin CA. Population Pharmacokinetics of Rifampin in the Treatment of Mycobacterium Tuberculosis in Elephants. Journal of Veterinary Pharmacology and Therapeutics 2015;38(2):137-43(PubMed link)

  39. Shao J, Markowitz JS, Bei D, and An G*. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014 Dec;103(12):3810-33 * Corresponding author.(PubMed link)

  40. An G*, Liu W, Katz D, Marek G, Awni W, and Dutta S. Population Pharmacokinetics of the Potent, Selective 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers following Single and Multiple Dose Regimens. Biopharmaceutics & Drug Disposition 2014 Oct;35(7):417-29. * Corresponding author (PubMed link)

  41. An G#, Wang X#, and Morris ME. Flavonoids are Inhibitors of Human Organic Anion Transporter 1 (OAT1). Drug Metabolism and Disposition 2014;42(9):1357-66. # contributed equally (PubMed link)

  42. Deng J, Shao J, Markowitz JS, and An G*. ABC Transporters in the Multi-drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors. Pharmaceutical Research 2014; 31 (9):2237-55 * Corresponding author. (PubMed link)

  43. Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F, Henegh, Shah A, Gevorkyan H, Jhee SS, Ereshefsky L, Marek GJ. Peripheral and central nervous system inhibition of 11?-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Translational Psychiatry 2013; 3:e295, 1-7.(PubMed link)

  44. An G*, Liu W, Katz D, Marek G, Awni W, and Dutta S. Effect of Ketoconazole on the Pharmacokinetics of ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study. Drug Metabolism and Disposition 2013; 41(5): 1035-45. * Corresponding author(PubMed link)

  45. An G and Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. The AAPS Journal 2012; 14(2):352-64.(PubMed link)

  46. Tsiklauri L, An G, Alaniya M, Kemertelidze E, Morris ME. Optimal Parameters of HPLC for Simultaneous Determination Robinin and Kaempferol. Pharmaceutical Chemistry Journal 2012,46(1):49-52.

  47. An G and Morris ME. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharmaceutics & Drug Disposition 2011; 32(8):446-457.(PubMed link)

  48. An G, Wu F, and Morris ME. 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharmaceutical Research 2011;28(5):1090-9.(PubMed link)

  49. An G, Gallegos J, and Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metabolism & Disposition 2011;39(3):426-32.(PubMed link)

  50. Tsiklauri L, An G, Ruszaj DM, Alaniya M, Kemertelidze E, Morris ME. Simultaneous determination of the flavonoids robinin and kaempferol in human breast cancer cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2011,55(1):109-13.(PubMed link)

  51. An G and Morris ME. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharmaceutical Research 2010;27(7): 1296-308.(PubMed link)

  52. An G, Ruszaj DM, and Morris ME. Interference of a sulfate conjugate in quantitative liquid chromatography/tandem mass spectrometry through in-source dissociation. Rapid Communications in Mass Spectrometry 2010; 24:1817-1819.(PubMed link)

  53. An G and Morris ME. The effect of isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharmaceutics & Drug Disposition 2010; 31:340-350.(PubMed link)

  54. An G and Morris ME. HPLC analysis of mitoxantrone in mouse plasma and tissues: Application in a pharmacokinetic study. J Pharm Biomed Anal 2010; 51(3): 750-3.(PubMed link)

  55. Moon YJ, Shin BS, An G and Morris ME. Biochanin A inhibits breast cancer tumor growth in a murine xenograft model. Pharmaceutical Research 2008; 25(9): 2158-63.(PubMed link)

  56. Yu Z, Chen B, Zhang W, Fang J, An G and Cai WM. Relative bioavailability and bioequivalence of ibuprofen orally disintegrating tablets in healthy volunteers. Chinese Journal of Clinical Pharmacy 2006;15(5): 280-283.

  57. Yu Z, Zhou P, Wang X, Xu D, Chen B, Zhang W, An G and Fang J. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult Chinese renal recipients. Chinese Journal of Clinical Pharmacology 2006;22(6): 243-247.

  58. Yu Z, Chen B, Zhang W, An G, Fang J, and Cai WM. Pharmacokinetics of Pazufloxacin Mesilate in Chinese Healthy Volunteers. Chinese Pharmaceutical Journal 2006; 41(15): 1168-1171.

  59. Di Q, Zhu B, An G, and Cai WM. The application status and future trend of parenteral nutrition preparation. China Pharmacy 2005; 16(11): 862-863

  60. An G, Ji MC, Geng XF, and Cheng NN. The cost-effective analysis of different antihyperglycemic therapies in patients with type 2 diabetes mellitus. Chinese Journal of Hospital Pharmacy J 2004; 24(7):423-424.

  61. An G, Geng XF, and Ji MC. Interactions of antihyperglycemic agents and drugs, Chinese Journal of Clinical Pharmacology 2003; 19(1): 67-70.

  62. An G, Geng XF, and Ji MC. Prescribing patterns and therapeutic implications in a cohort of 200 outpatients with type 2 diabetes and hypertension. Chinese Journal of Pharmacoepidemiology 2003; 12(2): 80-82.

  63. Ji MC, Geng XF, and An G. The rational drug use analysis in insomniac patients in comprehensive hospital. Chinese Academic Medical Magazine of Organisms 2002; 3:38-41.

  64. An G, Geng XF, and Ji MC. The application of evidence-based medicine in the drug therapy of type 2 Diabetes Mellitus. Chinese Academic Medical Magazine of Organisms 2002; 3: 57-59.

Abstracts

  1. Sieg AG, Strouse C, Mott SL, Reeder J, Sutamtewagul G, Link BK, Syrbu S, An G, Farooq U. Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study. ASH, Orlando, FL, Dec 7-10, 2019 [Poster abstract submitted]
  2. Bach T, Winokur P, An G. Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in handling complex nonlinear parent-metabolite pharmacokinetic model. AAPS, San Antonio, TX, Nov 2019 [Poster abstract accepted]
  3. Bhatt-Mehta V, Schumacher RE, An G, Zhu H. Methadone and Metabolite Concentration Correlation in Maternal and Cord Serum and Neonatal Abstinence Syndrome Outcomes. AAPS, San Antonio, TX, Nov 2019 [Poster abstract accepted]
  4. Widness JA, Mock DM, Kiosseva SV, Franco RS, Nalbant D, Schmidt RL, An G, Cress GA, Strauss RG, Cancelas JA. Induction of Anti-Biotin Labeled Red Blood Antibodies Shortens Post-Transfusion Red Cell Survival. AABB, San Antonio, TX, Nov 2019 [Poster abstract accepted]
  5. Bach T, Murry DJ, Winokur P, An G. Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults Following Single Ascending Doses. ACOP, Orlando, Oct 2019 [Poster abstract accepted]
  6. Alghamdi W, Al-Shaer M, An G, Alsultan A, Kipiani M, Kempker RR, Cegielski P, Peloquin CA. Population Pharmacokinetics of Linezolid in TB Patients:Dosing Regimens Simulation and Target Attainment Analysis International Workshop on Clinical Pharmacology of Tuberculosis Drugs. London, United Kingdom. Sep 10, 2019 [Poster abstract accepted]
  7. Alshaer M, Alghamdi W, Alsultan A, An G, Peloquin C. Ethionamide population pharmacokinetics model and monte carlo simulation in patients with multidrug-resistant tuberculosis. International Workshop on Clinical Pharmacology of Tuberculosis Drugs. London, United Kingdom. Sep 10, 2019 [Poster abstract accepted]
  8. Bach T, Jiang Y, Zhang X, An G. General Pharmacokinetic Features of Small Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD) – a Simulation-Based Study. AAPS, Washington DC, Nov 04-07, 2018
  9. Alghamdi W, Alshaer M, Sultan A, An G, Peloquin C. Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients. International Workshop on Clinical Pharmacology of Tuberculosis Drugs. The Hague, The Netherlands. Oct 23, 2018
  10. Alshaer M, Alghamdi W, Sultan A, An G, Peloquin C. Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: Experience from three US TB treatment centers. International Workshop on Clinical Pharmacology of Tuberculosis Drugs. The Hague, The Netherlands. Oct 23, 2018
  11. Carroll PD, Widness JA, Nalbant D, Gingerich EL, An G, Cress GA, Veng-Pedersen P. Availability of neonatal umbilical arterial catheter results in greater phlebotomy loss. Pediatric Academic Societies (PAS), San Francisco. May 5 - 8, 2018
  12. Suliman S, An G. Model-Based Meta-Analysis to Compare Primary Efficacy Endpoint and Efficacy Time Course for Opioids Used for Treatment of Osteoarthritis Pain. Health Sciences Research Week, Iowa City, April 17-18, 2018
  13. D'Cunha R, Widness JA, Yan X, Schmidt R, Veng-Pedersen P, An G. An integrated mechanism-based population pharmacokinetics model of erythropoietin in adults and premature neonates following multiple intravenous doses. ASCPT, Orlando, Mar 21-24, 2018.
  14. Bach T, Bae S, D'Cunha R, Winokur P, An G. The development of a liquid chromatography-tandem mass spectrometry method for the quantification of oxfendazole in human plasma. ASCPT, Orlando, Mar 21-24, 2018.
  15. Suliman S, An G. Model-Based Meta-Analysis to Compare Primary Efficacy Endpoint and Efficacy Time Course for Opioids Used for Treatment of Osteoarthritis Pain. AAPS, San Diego, Nov 12-15, 2017
  16. D'Cunha R, Bae S, Murry, DJ, and An G. Nilotinib Alters Efflux Transporter-Mediated Pharmacokinetics and Tissue Distribution of Afatinib in Mice. AAPS, San Diego, Nov 12-15, 2017
  17. D'Cunha R, and An G. A Whole-Body Physiologically Based Pharmacokinetic Model of Afatinib in Mice and Scale-Up to Humans. ACOP, Fort Lauderdale, Oct 15-18, 2017.
  18. Alsultan A, Neely M, Alghamdi WA, Alshaer M, Heysell S, Kempker RR, Mpagama SG, Kipiani M, Chongolo A, Houpt ER, An G, Peloquin C. Population pharmacokinetics of cycloserine. ACOP, Fort Lauderdale, Oct 15-18, 2017
  19. Bae S, D'Cunha R, and An G. Effect of 5,7-Dimethoxyflavone on Sorafenib Pharmacokinetics in Mice. ACCP, San Diego, Sep17 - 19, 2017
  20. Carroll PD, Widness JA, Nalbant D, Gingerich EL, An G, Cress GA, Veng-Pedersen P. Does Umbilical Arterial Catheter Use Result In Greater Phlebotomy Loss? Pediatric Academic Societies (PAS), San Francisco. May 06 - 09, 2017
  21. Jiang Y, Milavetz G, James MO, Stacpoole PW, and An G. A Semi-Mechanistic Pharmacokinetic Enzyme-Turnover Model for Dichloroacetic Acid (DCA) Auto-Inhibition in Rats. ACOP, Oct 22-26, 2016
  22. D’Cunha R, Bae S, and An G. TKI Combination Therapy: Strategy to Enhance Dasatinib Uptake by Inhibiting Pgp- and BCRP- Mediated Efflux. PGSRM, Kansas City. May 2016.
  23. Bae S, D’Cunha R, and An G. BCRP-mediated Interaction between Fruit Juice Ingredients and Pazopanib. Health Sciences Research Week, Iowa City, April 2016
  24. Bae S, D’Cunha R, and An G. Exploring the Synergy of TKIs Combination Therapy – A Pilot Study of Transporter-mediated Interaction between Dasatinib and Other TKIs in Vitro. ICRU, Iowa City, Nov 18, 2015.
  25. Awasthi R, An G, Donovan M, and Ponto L. An Effect-Compartment Modeling Approach to Relate the Plasma Concentrations of Delta-9-Tetrahydrocannabinol (THC) and Active Metabolite to the Observed Psychoactive Effects. AAPS, Orlando, Oct 25-29, 2015
  26. Fleisher B, Uum J, Shao J, and An G. Grapefruit Juice Ingredients Interact with Dasatinib through Inhibition of Breast Cancer Resistance Protein (BCRP): A New Type of Beverage-Drug Interaction. ASCPT, March 2015
  27. Uum J, Fleisher B, Shao J, and An G. Orange Juice and Apple Juice Ingredients Inhibit Dasatinib Efflux via P-Glycoprotein and Breast Cancer Resistance Protein: A New Type of Beverage-Drug Interaction. ASCPT, March 2015
  28. Bei D and An G. Quantification of 5,7-Dimethoxyflavone in Mouse Plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and its Application to a Pharmacokinetic Study. AAPS, San Diego, Nov 1-5, 2014
  29. Alsultan A, Derby R, An G, and Peloquin C. Bayesian Estimation of Levofloxacin Pharmacokinetics in Patients with Tuberculosis. ICAAC, 2014.
  30. Tsiklauri L.K., An G, Tsagareishvili G.V., Alaniya M, Kemertelidze E, Morris M.E. Investigation of Functional Role of Membrane Transporters in Oral Bioavailability of Robinin. III International Scientifi c and Practical Conference “Topical issues in medicine”, West Kazakhstan Marat Ospanov State Medical University. Aktobe, Kazakhstan, April 17-18, 2014
  31. Gottipati G, Lin C, Venitz J, Lesko L, and An G. Model-based Meta-analysis (MBMA) of Adverse Events (AE) and Dropouts (DO) for Drugs Evaluated for the Treatment of Fibromyalgia pain (FMP), ASCPT, Atlanta, Mar 18-21, 2014.
  32. Gottipati G, Trame, MN, Lin C, Venitz J, Lesko L, and An G. Model-based Meta-analysis (MBMA) of Efficacy at End-of-Trial and Efficacy-Time Course for Drugs Evaluated for the Treatment of Fibromyalgia pain (FMP). ASCPT, Atlanta, Mar 18-21, 2014. [Gottipati received Presidential Trainee Award for this poster].
  33. Deng J, Lesko L, and An G. A Physiologically Based Pharmacokinetic Model of Gefitinib Disposition: from Rat to Man. ASCPT, Atlanta, Mar 18-21, 2014.
  34. Deng J, Lesko L, and An G. Prediction of Gefitinib Human Pharmacokinetics From Animal Data - Comparative Assessment of Different Allometric Scaling Approaches. ASCPT, Atlanta, Mar 18-21, 2014.
  35. Shao J*, Deng J*, Bei D, and An G. Nilotinib is a dual P-gp and BCRP inhibitor and inhibits P-gp-mediated dasatinib efflux and BCRP-mediated gefitinib efflux. (*contributed equally) UF Health Cancer Center Research Poster Day. Gainesville, Mar 11, 2014
  36. Shao J, Deng J, Bei D, and An G. Exploring the Synergy of TKIs Combination Therapy – A Pilot Study of P-gp-mediated Interaction between Dasatinib and Imatinib in LLC PK1 Cells. UF COP Research Showcase. Gainesville, Feb 20, 2014.
  37. Cope J, Antigua A, Bushwitz J, An G, Patel A, and Zumberg M. Fondaparinux Use in Severe Renal Impairment and Renal Failure Requiring Renal Replacement Therapy. Society of Critical Care Medicine Annual Congress. San Francisco, January 9-13, 2014.
  38. Deng J, Lesko L, and An G. A Physiologically Based Pharmacokinetic Model of Gefitinib Disposition: from Rat to Man. Graduate Research Day, Gainesville, Oct 31st, 2013.
  39. Deng J, Jiang XL, Schmidt S, Lesko L, and An G. Physiologically-Based Pharmacokinetic Model for the CYP3A-mediated Inhibition of Midazolam Inhibition by Itraconazole. 9th Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 12-15, 2013.
  40. An G*, Wang X*, and Morris ME. Dietary Flavonoid Fisetin is a Substrate and Inhibitor of Human Organic Anion Transporter 1 (OAT1). (* contributed equally) AAPS, Chicago, Oct 14-18, 2012.
  41. An G, Liu W, Awni W, and Dutta S. Model-Based Meta-Analyses of Efficacy and Safety of COX-2 Inhibitors in Patients with Osteoarthritis Pain. AAPS, Chicago, Oct 14-18, 2012.
  42. Liu W, An G, Dutta S, Nothaft W, Duan R, Jain R, Awni W. ABT-652 Phase 2b Dose Selection Based on Exposure-Response Analyses of Efficacy, Safety (Heart Rate, Adverse Effects) and Dropout from Proof of Concept Study in Subjects with Osteoarthritic Pain. Abbott Day of Science and Technology, Chicago, Nov 14-15, 2011.
  43. An G and Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice: a mechanism-based model incorporating DNA and protein binding. ACoP, San Diego, April 3-6, 2011
  44. An G and Morris ME. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. AAPS, New Orleans, Nov 14-18, 2010
  45. An G and Morris ME. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). AAPS, New Orleans, Nov 14-18, 2010
  46. An G and Morris ME. A PBPK model of mitoxantrone in mice: a mechanism-based model incorporating macromolecule binding. Pharmacology Day, University at Buffalo, July 27, 2010
  47. An G and Morris ME. Determination of mitoxantrone in mouse plasma and tissues by an improved HPLC method and its application in a pharmacokinetic study. AAPS, Los Angeles, Nov 7-11, 2009
  48. An G and Morris ME. Transport and efflux of quercetin and biochanin A in MDCK cell monolayers- role of efflux transporters. AAPS, Los Angeles, Nov 7-11, 2009
  49. Liu JH, An G and Morris ME. The effect of flavonoids on transport of mitoxantrone in ABCG2 transfected MDCK cells. Sigma Xi, University at Buffalo, April, 2009
  50. An G and Morris ME. Inhibition of the BCRP-mediated transport of mitoxantrone by the flavonoids Biochanin A and Kaempferide. AAPS, Atlanta, Nov7-11, 2008.
  51. An G and Morris ME. Effect of multiple flavonoid combinations on Breast Cancer Resistance Protein (ABCG2) mediated transport. AAPS, Atlanta, Nov 7-11, 2008